RETATRUTIDE 10MG (1 VIAL): The Triple Agonist That’s Outperforming Tirzepatide
Reta is an investigational drug, still in clinical trials, that acts as a triple agonist targeting three different receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.
Key Features
- Lab-tested >99% purity
- Independent HPLC verification
- USA synthesized
- Cold-chain shipping
Premium research compound manufactured in the USA. Strictly for laboratory research and development purposes. Not for human or animal consumption.
Certificate of Analysis
Batch #VOX-0191 tested Jun 2026.
- Purity: >99.6%
- Mass Spectrometry: Passed
>99.6% Purity
Verified by independent labs
USA Made
Synthesized in domestic facilities
About This Product
Reta 10MG (1 Vial) – Buy Online in the USA | Limited-Time Offer
Reta 10MG from ASN-LABS is a high-quality research peptide available in a sterile 1-vial format. Known for its potential in metabolic and weight management studies, Reta is lab-tested to ensure purity and reliability. Perfect for researchers seeking consistent results, this product comes with fast, discreet shipping across the USA, including all 50 states.
Key Features of Reta 10MG:
-
Potency: 10MG (1 vial)
-
Use: Research peptide for metabolic studies
-
Purity: Third-party lab-tested
-
Nationwide USA Shipping – Discreet & secure
- Mechanism of action: It works by mimicking the actions of the natural gut hormones GLP-1, GIP, and glucagon, which play crucial roles in regulating blood sugar, appetite, and metabolism. This triple agonism contributes to increased insulin secretion, improved glucose homeostasis, appetite modulation, and increased energy expenditure.
- Potential uses: It is being investigated for the treatment of obesity and type 2 diabetes.
- Side effects: Common side effects are mainly gastrointestinal and include nausea, vomiting, diarrhea, and constipation, says canadianinsulin.com. These are typically mild to moderate and can be managed with dose adjustments.
- Availability: Reta is not yet FDA approved. It is currently in Phase 3 clinical trials, which are expected to conclude in early 2026. If approved, it could be available by 2027.
- Administration: It's administered as a weekly subcutaneous injection, typically starting with a lower dose that's gradually increased.
Customer Reviews
Be the first to review
Reviews
There are no reviews yet.